<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kawasaki disease: Clinical features and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kawasaki disease: Clinical features and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kawasaki disease: Clinical features and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Sundel, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marisa Klein-Gitelman, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 10, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Kawasaki disease (KD, previously called mucocutaneous lymph node syndrome) is one of the most common vasculitides of childhood [<a href="#rid1">1</a>]. KD also occurs rarely in adults. It is typically a self-limited condition, with fever and manifestations of acute inflammation lasting for an average of 12 days without therapy [<a href="#rid2">2</a>]. However, complications such as coronary artery (CA) aneurysms, depressed myocardial contractility and heart failure, myocardial infarction, arrhythmias, and peripheral arterial occlusion may develop and lead to significant morbidity and mortality. (See  <a class="medical medical_review" href="/z/d/html/5772.html" rel="external">"Cardiovascular sequelae of Kawasaki disease: Clinical features and evaluation"</a>.)</p><p>The clinical manifestations and diagnosis of KD are discussed in this topic review. The epidemiology, etiology, treatment, and complications of KD, including cardiac sequelae, are presented separately. Incomplete (atypical) KD and unique features in infants and adults are also reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/6416.html" rel="external">"Kawasaki disease: Epidemiology and etiology"</a> and  <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">"Kawasaki disease: Initial treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/5772.html" rel="external">"Cardiovascular sequelae of Kawasaki disease: Clinical features and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/15689.html" rel="external">"Incomplete (atypical) Kawasaki disease"</a> and  <a class="medical medical_review" href="/z/d/html/15688.html" rel="external">"Kawasaki disease: Complications"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical features of KD reflect widespread inflammation of primarily medium-sized muscular arteries. Diagnosis is based upon evidence of systemic inflammation (eg, fever) in association with signs of mucocutaneous inflammation. The characteristic bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, rash, extremity changes, and cervical lymphadenopathy typically develop after a brief nonspecific prodrome of respiratory or gastrointestinal symptoms [<a href="#rid3">3-8</a>] (see <a class="local">'Other findings'</a> below). These characteristic clinical signs are the basis for the diagnostic criteria for KD  (<a class="graphic graphic_table graphicRef67711" href="/z/d/graphic/67711.html" rel="external">table 1</a>) [<a href="#rid9">9</a>].</p><p>Variations in age have the greatest impact on a patient's likelihood of developing mucocutaneous manifestations of KD. Oral mucous membrane findings are seen in approximately 90 percent of cases of KD, polymorphous rash in 70 to 90 percent, extremity changes in 50 to 85 percent, ocular changes in &gt;75 percent, and cervical lymphadenopathy in 25 to 70 percent [<a href="#rid7">7,10-12</a>].</p><p>These findings are often not present at the same time, and there is no typical order of appearance. As an example, some patients have only developed fever and cervical lymphadenopathy by the time of admission (so-called KD with isolated cervical lymphadenopathy, KDiL) [<a href="#rid13">13</a>]. In one case series, these patients tended to be older and to have a more severe course, with increased risk of coronary artery (CA) disease and lack of response to intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG). Thus, repeated histories and physical examinations are important both for making a timely diagnosis of KD in children who fail to meet diagnostic criteria, as well as for appropriate consideration of alternative diagnoses. (See <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h2">Fever</span><span class="headingEndMark"> — </span>An elevated body temperature is the most consistent manifestation of KD. Fever is minimally responsive to antipyretic agents, and it typically remains above 38.5ºC (101.3ºF) during most of the illness. On the other hand, fever may be intermittent and may be missed by parents who use tympanic, temporal, axillary, or similar temperature measurement methods that are less reliable than oral or rectal methods. Thus, the diagnosis should be considered in all children with prolonged, unexplained fever ≥5 days but should still be considered in seemingly afebrile children who have other findings consistent with KD. (See  <a class="medical medical_review" href="/z/d/html/15689.html" rel="external">"Incomplete (atypical) Kawasaki disease"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Conjunctivitis</span><span class="headingEndMark"> — </span>Bilateral nonexudative conjunctivitis is present in more than 90 percent of patients. A predominantly bulbar injection typically begins within days of the onset of fever, and the eyes often have a brilliant erythema, which characteristically spares the limbus  (<a class="graphic graphic_picture graphicRef78898" href="/z/d/graphic/78898.html" rel="external">picture 1</a>). Children also are frequently photophobic. In addition, anterior uveitis may develop in up to 70 percent of children with ocular findings [<a href="#rid12">12,14</a>]; therefore, slit-lamp examination may be helpful in ambiguous cases. The presence of uveitis provides further evidence for the diagnosis of KD since it is more commonly seen in KD than in other diseases with similar presentations. (See  <a class="medical medical_review" href="/z/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Mucositis</span><span class="headingEndMark"> — </span>Mucositis often becomes evident as KD progresses. Cracked, red lips  (<a class="graphic graphic_picture graphicRef59319" href="/z/d/graphic/59319.html" rel="external">picture 2</a>) and a "strawberry tongue"  (<a class="graphic graphic_picture graphicRef68321" href="/z/d/graphic/68321.html" rel="external">picture 3</a>) are characteristic. The latter is a result of sloughing of filiform papillae and denuding of the inflamed glossal tissue. The bumps on the "strawberry" are the remaining fungiform papillae. These manifestations of oral mucositis may occur singly, in a very mild form, or not at all. Discrete oral lesions, such as vesicles or ulcers, and tonsillar exudate are suggestive of a disease process other than KD [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Rash</span><span class="headingEndMark"> — </span>The cutaneous manifestations of KD are polymorphous. The rash usually begins during the first few days of illness, typically as perineal erythema and desquamation, followed by macular, morbilliform, or targetoid skin lesions of the trunk and extremities. Vesicular or bullous lesions generally are not observed, but KD may trigger a psoriasiform eruption in children not previously recognized to have psoriasis [<a href="#rid15">15-19</a>]. Patients may also have redness or crust formation at the site of Bacille Calmette-Guérin (BCG) inoculation. This finding is more useful for increasing the level of suspicion for KD in countries where <a class="drug drug_pediatric" data-topicid="105601" href="/z/d/drug information/105601.html" rel="external">BCG vaccine</a> is routinely given. (See <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H7"><span class="h2">Extremity changes</span><span class="headingEndMark"> — </span>Changes of the extremities are generally the last manifestation to appear. Children develop an indurated edema of the dorsum of their hands and feet  (<a class="graphic graphic_picture graphicRef72040" href="/z/d/graphic/72040.html" rel="external">picture 4</a>) and a diffuse erythema of their palms and soles.</p><p>The convalescent phase of KD is often characterized by sheet-like desquamation that begins in the periungual region of the hands and feet  (<a class="graphic graphic_picture graphicRef53452" href="/z/d/graphic/53452.html" rel="external">picture 5</a>) and by linear nail creases (Beau's lines). The prevalence of periungual desquamation in patients with KD has been reported to vary from 68 to 98 percent [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Lymphadenopathy</span><span class="headingEndMark"> — </span>Cervical lymphadenopathy is the least consistent feature of KD, absent in as many as one-half to three-quarters of children with the disease, especially those under one year of age [<a href="#rid11">11</a>]. When present, lymphadenopathy tends to primarily involve the anterior cervical nodes overlying the sternocleidomastoid muscles [<a href="#rid21">21</a>]. Often, only a single, large node is palpable, although ultrasound imaging of the neck typically reveals numerous discrete nodes arranged like a bunch of grapes [<a href="#rid22">22</a>].</p><p>Diffuse lymphadenopathy or other signs of reticuloendothelial involvement (eg, splenomegaly) should prompt a search for alternative diagnoses. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H3460119"><span class="h2">Cardiovascular findings</span><span class="headingEndMark"> — </span>Cardiovascular findings are not part of the diagnostic criteria of KD, but they support the diagnosis since most conditions that mimic KD do not involve the heart. Cardiac manifestations during the first week to 10 days of illness may include tachycardia out of proportion to the degree of fever and gallop sounds [<a href="#rid2">2</a>]. These physical exam findings are the result of lymphocytic myocarditis that is ubiquitous in children with KD. In addition, heart sounds may be muffled due to a pericardial effusion, which is detected in approximately 30 percent of children with KD. Such effusions are usually small; significant fluid collections and tamponade are rare.</p><p>With improved echocardiographic techniques and better understanding of age and sex norms for CA diameters, approximately 30 percent of patients with KD are found to have CA dilatation at diagnosis [<a href="#rid23">23,24</a>]. Frank aneurysms are usually not seen until after day 10 of illness. Severely ill patients, particularly young infants, may develop fusiform aneurysms of other nonvisceral medium-sized arteries, most characteristically involving the brachial arteries. These are easily palpable or visible in the axillae, although they may be mistaken for enlarged lymph nodes. In addition, young infants may have cold, pale, or cyanotic digits of the hands and feet due to reduced perfusion. Gangrene may, in rare cases, cause loss of fingers or toes during this acute period. The cardiac complications associated with KD are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/15688.html" rel="external">"Kawasaki disease: Complications", section on 'Cardiac complications'</a> and  <a class="medical medical_review" href="/z/d/html/5772.html" rel="external">"Cardiovascular sequelae of Kawasaki disease: Clinical features and evaluation"</a>.)</p><p class="headingAnchor" id="H2138542523"><span class="h2">Arthritis</span><span class="headingEndMark"> — </span>Arthritis is not included in the diagnostic criteria but has been reported in 7.5 to 25 percent of patients with KD [<a href="#rid25">25,26</a>]. The prevalence of arthritis was 7.5 percent in a retrospective Canadian study of 414 consecutive patients diagnosed with KD [<a href="#rid25">25</a>]. The large joints (ie, knee, ankle, and hip) were primarily involved. Oligoarticular involvement (arthritis of four or fewer joints) occurred in 16 patients and polyarticular involvement (arthritis of five or more joints) in 15 patients. With only very rare exceptions, the arthritis is self-limited and nondeforming. Patients with arthritis were more likely to have increased levels of inflammatory markers (C-reactive protein [CRP] or erythrocyte sedimentation rate [ESR]) and neutrophils. Otherwise, there were no differences in clinical features, response to therapy, or clinical outcomes between patients with or without arthritis.</p><p class="headingAnchor" id="H9"><span class="h2">Other findings</span><span class="headingEndMark"> — </span>The following nonspecific symptoms commonly occur during the prodrome of the illness, 7 to 10 days before the typical mucocutaneous features develop [<a href="#rid2">2,5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Diarrhea, vomiting, or abdominal pain – 61 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Irritability – 50 percent (older children with KD more commonly present with lethargy than irritability)</p><p class="bulletIndent1"><span class="glyph">●</span>Vomiting alone – 44 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Cough or rhinorrhea – 35 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased oral intake – 37 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Joint pain – 15 percent</p><p></p><p>Patients with gastrointestinal involvement often have pseudo-obstruction on radiologic studies [<a href="#rid27">27</a>]. The presentation of gastrointestinal symptoms before typical KD features may delay the diagnosis and lead to unnecessary invasive procedures including surgery.</p><p class="headingAnchor" id="H2867630539"><span class="h2">Infants</span><span class="headingEndMark"> — </span>Infants are at increased risk of CA aneurysms, possibly in part because of delay in treatment due to their lack of complete diagnostic criteria [<a href="#rid28">28-31</a>]. In a retrospective Taiwanese study of 120 patients with KD that included 20 infants ≤6 months of age, for example, the infants were more likely to present with incomplete KD than patients older than six months of age (35 versus 12 percent), have CA involvement (65 versus 19 percent), and receive late <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a> therapy [<a href="#rid30">30</a>]. Even in infants diagnosed and treated before the 10<sup>th</sup> day of illness, the incidence of CA abnormalities is significantly higher than it is in older patients. In a retrospective study of 720 children with KD, 88 of whom were &lt;6 months of age, a larger proportion of infants &lt;6 months old had a dilated or aneurysmal CA on the initial echocardiogram compared with those ≥6 months old (43.4 versus 19.5 percent) [<a href="#rid32">32</a>]. Of infants &lt;6 months old who had a normal echocardiogram at diagnosis, 18.6 percent developed a dilated or aneurysmal CA on a subsequent echocardiogram within eight weeks of diagnosis.</p><p class="headingAnchor" id="H2203350907"><span class="h2">Adults</span><span class="headingEndMark"> — </span>Approximately one-fourth of adult KD cases have occurred in patients with human immunodeficiency virus (HIV) infection [<a href="#rid33">33</a>]. One review found that cervical lymphadenopathy, hepatitis, and arthralgia were all more common in adults with KD than in children, and meningitis, thrombocytosis, and CA aneurysms were less common [<a href="#rid34">34</a>]. A subsequent review of 43 adult patients with KD in France, which excluded cases associated with HIV, found more sobering outcomes [<a href="#rid35">35</a>]. The median time to diagnosis was 13 days, and morbidity was correspondingly high: 26 percent of patients demonstrated CA vasculitis, 19 percent had CA aneurysms, and 9 percent had a myocardial infarction. Patients diagnosed before day 10, however, had outcomes similar to those seen in children. In a separate case report, splenomegaly and elevated serum ferritin levels were reported in one adult patient, most likely due to macrophage activation syndrome (MAS) complicating KD [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/15688.html" rel="external">"Kawasaki disease: Complications", section on 'Macrophage activation syndrome'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">LABORATORY FINDINGS</span><span class="headingEndMark"> — </span>No laboratory studies are included among the diagnostic criteria for typical KD. However, certain findings may support the diagnosis of KD, particularly in incomplete cases [<a href="#rid1">1</a>] (see <a class="local">'Diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/15689.html" rel="external">"Incomplete (atypical) Kawasaki disease", section on 'Laboratory tests'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic inflammation is characteristic of KD. Typical manifestations include elevation of acute-phase reactants (eg, C-reactive protein [CRP] or erythrocyte sedimentation rate [ESR]), thrombocytosis that generally develops after the seventh day of illness, leukocytosis, and a left-shift (increased immature neutrophils) in the white blood cell (WBC) count.</p><p></p><p class="bulletIndent1">CRP elevations resolve well before ESR does. However, patients with more severe disease can have persistently high levels of CRP for weeks. Treatment with intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG) usually raises the ESR, so this lab test should not be measured after a child receives IVIG. On the other hand, control of inflammation by IVIG accelerates the decrease in CRP, making this a more useful marker of disease activity in a treated child.</p><p></p><p class="bulletIndent1">Ferritin is another acute-phase reactant that is elevated in inflammatory conditions such as KD, usually less than five times the upper limit of normal. Much higher values, typically &gt;5000 ng/mL, are seen in macrophage activation syndrome (MAS). This serious but rare complication of KD is associated with an increased resistance to <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> treatment and an increased risk of CA abnormalities. Elevations of that magnitude are essentially diagnostic of MAS in the setting of KD. (See  <a class="medical medical_review" href="/z/d/html/15688.html" rel="external">"Kawasaki disease: Complications", section on 'Macrophage activation syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/87499.html" rel="external">"Clinical features and diagnosis of hemophagocytic lymphohistiocytosis", section on 'Rheumatologic disorders/MAS'</a>.)</p><p></p><p class="bulletIndent1">Lymphocyte numbers typically drop during the acute phase of KD, then rise dramatically during convalescence. Early in the course of disease, a complete blood count with a lymphocytic rather than neutrophilic preponderance is more suggestive of a viral illness. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1">Platelet counts generally rise by the second week of illness and may reach 1,000,000/mm<sup>3</sup> (reactive thrombocytosis) in the most severe cases. In some studies, the degree of thrombocytosis correlates with the risk of coronary artery (CA) changes in KD. On the other hand, rare children with KD develop thrombocytopenia due to a consumptive coagulopathy. These patients are at significantly increased risk of morbidity and mortality, particularly the development of CA abnormalities [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/15688.html" rel="external">"Kawasaki disease: Complications", section on 'Cardiac complications'</a>.)</p><p></p><p class="bulletIndent1">Thrombocytopenia, high triglycerides, low sodium, elevated liver function tests, and monocytes/macrophages in cerebral spinal fluid (CSF) can all be signs of subclinical MAS and may warrant further diagnostic testing. (See  <a class="medical medical_review" href="/z/d/html/15688.html" rel="external">"Kawasaki disease: Complications", section on 'Macrophage activation syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with KD often present with a normocytic, normochromic anemia. Hemoglobin concentrations more than two standard deviations below the mean for age are noted in one-half of patients within the first two weeks of illness  (<a class="graphic graphic_table graphicRef101544" href="/z/d/graphic/101544.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinary microscopy commonly reveals WBCs [<a href="#rid38">38</a>]. Pyuria is usually of urethral origin and therefore may be missed on urinalyses obtained by bladder tap or catheterization [<a href="#rid39">39</a>]. The WBCs are not polymorphonuclear leukocytes and therefore are not detected by dipstick tests for leukocyte esterase. Thus, children with suspected KD should have a clean voided or bagged urine specimen collected for microscopic examination in order to detect this characteristic feature.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one retrospective series of 259 patients, 45 percent had at least one abnormal liver function test [<a href="#rid40">40</a>]. In a case-control series, approximately 30 percent of 280 patients with KD had mild-to-moderate elevation of transaminases (eg, serum alanine aminotransferase &gt;50 units/L) [<a href="#rid6">6</a>]. The reason for this transaminitis is unclear. In addition, a minority of children develop obstructive jaundice from hydrops of the gallbladder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CSF may display a mononuclear pleocytosis without hypoglycorrhachia (decreased CSF glucose) or elevation of CSF protein. In a retrospective review, 46 of 520 children with KD underwent lumbar puncture [<a href="#rid41">41</a>]. In this subset of patients, 39 percent had elevated CSF WBC counts. The median count was 22.5 cells/mm<sup>3</sup> with 6 percent neutrophils and 92 percent mononuclear cells, although cell counts as high as 320/mm<sup>3</sup> with up to 79 percent neutrophils were reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, arthrocentesis of inflamed joints in KD typically demonstrates a pleocytosis, with 125,000 to 300,000 WBCs/mm<sup>3</sup>, primarily neutrophils [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with KD develop significant perturbations in serum lipid profiles, including elevated triglycerides and low-density lipoproteins, and depressed high-density lipoproteins [<a href="#rid2">2,43-45</a>], as is often observed in a variety of infectious and inflammatory conditions. A return to normal generally occurs within weeks or months following <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">IVIG</a> therapy, though abnormalities may persist for years in children who are not treated with IVIG [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyponatremia (serum sodium &lt;135 mEq/L) may be seen and is associated with an increased risk of CA aneurysms [<a href="#rid46">46</a>].</p><p></p><p class="headingAnchor" id="H26262883"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Diagnosis of KD according to the criteria established by Tomisaku Kawasaki in 1967 [<a href="#rid47">47</a>] requires the presence of fever lasting ≥5 days, combined with at least four of the five following physical findings, without an alternative explanation  (<a class="graphic graphic_table graphicRef67711" href="/z/d/graphic/67711.html" rel="external">table 1</a>) [<a href="#rid1">1,2,48</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral bulbar conjunctival injection  (<a class="graphic graphic_picture graphicRef78898" href="/z/d/graphic/78898.html" rel="external">picture 1</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral mucous membrane changes, including injected or fissured lips  (<a class="graphic graphic_picture graphicRef59319" href="/z/d/graphic/59319.html" rel="external">picture 2</a>), injected pharynx, or strawberry tongue  (<a class="graphic graphic_picture graphicRef68321" href="/z/d/graphic/68321.html" rel="external">picture 3</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral extremity changes, including erythema of palms or soles, edema of hands or feet (acute phase)  (<a class="graphic graphic_picture graphicRef72040" href="/z/d/graphic/72040.html" rel="external">picture 4</a>), or periungual desquamation (convalescent phase)  (<a class="graphic graphic_picture graphicRef53452" href="/z/d/graphic/53452.html" rel="external">picture 5</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polymorphous rash</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cervical lymphadenopathy (at least one lymph node &gt;1.5 cm in diameter)</p><p></p><p>Approximately 40 percent of children with KD have a concurrent infection. Ascribing the fever to such an infection or to KD requires clinical judgement. </p><p>Redness or crust formation at the site of Bacille Calmette-Guérin (BCG) inoculation is also suggested as a useful sign in several diagnostic guidelines [<a href="#rid2">2,9</a>]. In one series of 15,524 patients with KD and a history of BCG vaccination, 50 percent had this finding compared with none of the 53 children admitted with respiratory syncytial virus or rotavirus infection who served as the control group [<a href="#rid19">19</a>].</p><p>Rash and conjunctival injection are seen with many illnesses, but other KD features, such as red, cracked lips and redness and swelling of the hands and feet, are unusual in the illnesses in the differential diagnosis and should increase the suspicion for KD. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H3449497313"><span class="h2">Typical versus incomplete KD</span><span class="headingEndMark"> — </span>As with all clinical criteria, these are imperfect guidelines with less than 100 percent sensitivity and specificity. In addition, Dr. Kawasaki published his guidelines before cardiac involvement was recognized in this disease, so they were never intended to identify children at risk for developing coronary artery (CA) abnormalities. Thus, it is not surprising that at least 10 percent of children who develop CA aneurysms never meet criteria for KD [<a href="#rid49">49</a>]. Incomplete KD should be suspected in patients less than six months of age with unexplained fever ≥7 days, even if they have no clinical findings of KD, and in patients of any age with unexplained fever ≥5 days and only two or three clinical criteria. An algorithmic approach can help identify such cases  (<a class="graphic graphic_algorithm graphicRef115617" href="/z/d/graphic/115617.html" rel="external">algorithm 1</a>) [<a href="#rid2">2</a>] and thereby significantly decrease the number of children who develop CA abnormalities despite not meeting criteria for the disease. (See  <a class="medical medical_review" href="/z/d/html/15689.html" rel="external">"Incomplete (atypical) Kawasaki disease"</a>.)</p><p class="headingAnchor" id="H841490159"><span class="h2">Laboratory evaluation</span><span class="headingEndMark"> — </span>As noted above, Dr. Kawasaki identified the first 50 cases of "mucocutaneous lymph node syndrome" on the basis of clinical findings rather than laboratory or imaging studies [<a href="#rid47">47</a>]. Thus, no laboratory values are included in the classical diagnostic criteria, but they nonetheless may support a diagnosis of KD in ambiguous cases. In fact, some laboratory tests are explicitly included in the algorithm for diagnosis of atypical KD  (<a class="graphic graphic_algorithm graphicRef115617" href="/z/d/graphic/115617.html" rel="external">algorithm 1</a>) [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/15689.html" rel="external">"Incomplete (atypical) Kawasaki disease", section on 'Laboratory tests'</a>.)</p><p>The following blood tests are typically obtained on children in whom a diagnosis of KD is being considered:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood counts with differential white blood cell (WBC) counts</p><p class="bulletIndent1"><span class="glyph">●</span>Liver function tests including aspartate transaminase (AST), alanine transaminase (ALT), and albumin</p><p class="bulletIndent1"><span class="glyph">●</span>C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)</p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis</p><p></p><p>Elevated WBC and platelet counts, transaminases, and acute-phase reactants, as well as anemia and pyuria, are suggestive of KD.</p><p>In addition, when specific mimics of KD are strongly suspected, studies that are more specific for these alternative diagnoses may help confirm the diagnosis. These can include rapid viral testing (eg, adenovirus), serologic testing for leptospirosis and other bacterial infections, and blood cultures. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with an emerging syndrome (multisystem inflammatory syndrome in children [MIS-C]) of persistent fever, systemic inflammation, and multiorgan failure children with some features of KD [<a href="#rid50">50</a>]. Polymerase chain reaction (PCR) testing for SARS-CoV-2 should be performed in children who present with features of MIS-C, particularly if there is evidence of coronavirus disease 19 (COVID-19) exposure. (See  <a class="medical medical_review" href="/z/d/html/128190.html" rel="external">"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis"</a>.)</p><p class="headingAnchor" id="H4123938563"><span class="h2">Echocardiography</span><span class="headingEndMark"> — </span>Echocardiography should be performed in all patients with KD as soon as the diagnosis is suspected in order to establish a reference point for longitudinal follow-up  (<a class="graphic graphic_algorithm graphicRef115617" href="/z/d/graphic/115617.html" rel="external">algorithm 1</a>) and treatment efficacy. In addition, initial CA diameter is a factor in identifying patients at high risk of developing a coronary aneurysm and therefore warranting augmentation of initial intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG) therapy (see  <a class="medical medical_review" href="/z/d/html/15688.html" rel="external">"Kawasaki disease: Complications", section on 'Coronary artery abnormalities'</a> and  <a class="medical medical_review" href="/z/d/html/5772.html" rel="external">"Cardiovascular sequelae of Kawasaki disease: Clinical features and evaluation", section on 'Risk factors'</a>). Finally, CA diameters are useful for identifying patients who should be treated with IVIG despite failing to meet classical diagnostic criteria for KD. Echocardiographic evaluation for KD is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5772.html" rel="external">"Cardiovascular sequelae of Kawasaki disease: Clinical features and evaluation", section on 'Initial evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/15689.html" rel="external">"Incomplete (atypical) Kawasaki disease", section on 'Echocardiography'</a>.)</p><p class="headingAnchor" id="H26263419"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>KD is most commonly confused with infectious exanthems of childhood [<a href="#rid2">2,51,52</a>]. Early in the course, KD is often mistaken for more routine childhood illnesses, such as viral gastroenteritis, viral upper respiratory tract infection, or pneumonia, depending upon the other presenting symptoms, such as vomiting or cough. Concurrent viral infections are common, and, therefore, the presence of respiratory symptoms or positive respiratory viral polymerase chain reaction (PCR) testing does not exclude the diagnosis of KD [<a href="#rid53">53</a>]. Meningitis is sometimes suspected due to irritability.</p><p>Infectious diseases and other mimics of KD may have the following clinical features not commonly found in KD [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Exudative conjunctivitis (eg, adenovirus)</p><p class="bulletIndent1"><span class="glyph">●</span>Exudative pharyngitis (eg, streptococcal pharyngitis)</p><p class="bulletIndent1"><span class="glyph">●</span>Discrete intraoral lesions (eg, Koplik spots in measles)</p><p class="bulletIndent1"><span class="glyph">●</span>Bullous or vesicular rash (eg, Stevens-Johnson syndrome [SJS])</p><p class="bulletIndent1"><span class="glyph">●</span>Generalized lymphadenopathy (eg, Epstein-Barr virus [EBV] infection)</p><p></p><p>The presence of any of these findings and/or the absence of fever should suggest a diagnosis other than KD. Of note, concurrent infections (both viral and bacterial) are common in patients with KD, found in up to 33 percent of children in one study [<a href="#rid54">54</a>]. In this retrospective analysis of 129 consecutive children seen with KD in Toronto, infection at the time of diagnosis did not affect response to therapy or outcome. In any event, diagnosis of an infectious condition does not preclude a concurrent diagnosis of KD.</p><p>The differential diagnosis of KD includes  (<a class="graphic graphic_table graphicRef53802" href="/z/d/graphic/53802.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Measles, echovirus, adenovirus [<a href="#rid55">55</a>], and EBV – These viral illnesses may share many of the signs of mucocutaneous inflammation, but they typically have less evidence of systemic inflammation and generally lack the extremity changes seen in KD. In addition, EBV typically causes a polyclonal gammopathy while serum immunoglobulin G (IgG) in KD is usually low or low normal [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/z/d/html/3021.html" rel="external">"Measles: Clinical manifestations, diagnosis, treatment, and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/2693.html" rel="external">"Enterovirus and parechovirus infections: Clinical features, laboratory diagnosis, treatment, and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/8339.html" rel="external">"Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection"</a> and  <a class="medical medical_review" href="/z/d/html/8283.html" rel="external">"Clinical manifestations and treatment of Epstein-Barr virus infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Toxin-mediated illnesses, especially group A streptococcal infections (eg, scarlet fever and toxic shock syndrome) – These usually lack the ocular and articular involvement typical of KD, though patients with staphylococcal toxic shock syndrome occasionally have conjunctival erythema. Patients with toxic shock often have generalized edema. The edema is rarely confined to the hands and feet, as it is in children with KD. Patients with scarlet fever may have periungual desquamation. (See  <a class="medical medical_review" href="/z/d/html/3162.html" rel="external">"Invasive group A streptococcal infection and toxic shock syndrome: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3161.html" rel="external">"Staphylococcal toxic shock syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/6068.html" rel="external">"Invasive group A streptococcal infections in children", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rocky Mountain spotted fever and leptospirosis – Headache and gastrointestinal complaints typically are prominent features of these infections. (See  <a class="medical medical_review" href="/z/d/html/7904.html" rel="external">"Clinical manifestations and diagnosis of Rocky Mountain spotted fever"</a> and  <a class="medical medical_review" href="/z/d/html/5527.html" rel="external">"Leptospirosis: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug reactions such as SJS or serum sickness – These may mimic KD but with subtle differences in the ocular and mucosal manifestations, such as keratitis in SJS rather than uveitis in KD. Further, laboratory markers of inflammation are generally normal or only mildly elevated. (See  <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic juvenile idiopathic arthritis (JIA) – Children with this condition generally lack the conjunctival and oral findings of KD. Lymphadenopathy also is generalized, and it may be accompanied by splenomegaly, unlike in KD. While systemic JIA is not generally associated with cardiac involvement other than pericarditis, several case reports have documented moderate coronary involvement (Z-score &lt;3.0) in children with systemic JIA [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/6413.html" rel="external">"Systemic juvenile idiopathic arthritis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H3501660"><span class="h2">Delayed diagnosis</span><span class="headingEndMark"> — </span>Treatment with intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG) within the first 10 days of illness reduces the prevalence of coronary artery (CA) aneurysms fivefold compared with children not treated with IVIG [<a href="#rid58">58,59</a>]. Thus, it is desirable to diagnose KD as soon as possible after the onset of symptoms in order to initiate treatment and reduce the risk of CA lesions [<a href="#rid60">60</a>]. However, timely identification is challenging because the diagnosis is based upon nonspecific clinical signs and there is no definitive diagnostic test. Thus, the clinicians in a medical facility with the most experience taking care of patients with KD should be consulted as early as possible in the course of the evaluation of suspected KD. These clinicians may include pediatric rheumatologists, infectious disease specialists, cardiologists, and/or hospitalists, depending upon the institution.</p><p>In a retrospective study of 562 patients diagnosed with KD at eight North American centers, 92 cases (16 percent) were diagnosed after the first 10 days of illness (ie, late diagnosis) [<a href="#rid61">61</a>]. Predictors of a delay in diagnosis of KD included age below six months, clinical presentation of incomplete KD, greater distance from a tertiary center, and variability between clinical centers. In contrast, socioeconomic status was not associated with a delay in diagnosis.</p><p>These findings suggest that practice variation in confirming a diagnosis of KD may in part contribute to a delayed diagnosis. The results of this study underscore the need for a high index of suspicion of KD, especially in young infants and patients who present with incomplete KD, in order to identify and treat patients in a timely manner. (See  <a class="medical medical_review" href="/z/d/html/15689.html" rel="external">"Incomplete (atypical) Kawasaki disease"</a>.)</p><p class="headingAnchor" id="H4202099461"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110198.html" rel="external">"Society guideline links: Kawasaki disease"</a>.)</p><p class="headingAnchor" id="H114634195"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/17130.html" rel="external">"Patient education: Kawasaki disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3458787"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Kawasaki disease (KD, also called mucocutaneous lymph node syndrome) is one of the most common vasculitides of childhood. KD occurs only rarely in adults. It is typically a self-limited condition, with fever and manifestations of acute inflammation lasting for an average of 12 days without therapy. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – KD is characterized by systemic inflammation manifested by fever and mucocutaneous involvement, including bilateral nonexudative conjunctivitis  (<a class="graphic graphic_picture graphicRef78898" href="/z/d/graphic/78898.html" rel="external">picture 1</a>), erythema of the lips and oral mucosa  (<a class="graphic graphic_picture graphicRef59319" href="/z/d/graphic/59319.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef68321" href="/z/d/graphic/68321.html" rel="external">picture 3</a>), polymorphous rash, extremity changes  (<a class="graphic graphic_picture graphicRef72040" href="/z/d/graphic/72040.html" rel="external">picture 4</a> and <a class="graphic graphic_picture graphicRef53452" href="/z/d/graphic/53452.html" rel="external">picture 5</a>), and cervical lymphadenopathy  (<a class="graphic graphic_table graphicRef67711" href="/z/d/graphic/67711.html" rel="external">table 1</a>). These findings are often not present at the same time. Thus, repeated histories and physical examinations are important in making a timely diagnosis of KD in children with fever and signs of mucocutaneous inflammation. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory findings</strong> – No laboratory studies are included among the diagnostic criteria for typical KD. However, the presence of compatible laboratory features strongly supports the diagnosis. (See <a class="local">'Laboratory findings'</a> above and  <a class="medical medical_review" href="/z/d/html/15689.html" rel="external">"Incomplete (atypical) Kawasaki disease", section on 'Laboratory tests'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of KD according to classical criteria requires the presence of fever ≥5 days, combined with at least four of the other five signs of mucocutaneous inflammation, without any other explanation  (<a class="graphic graphic_table graphicRef67711" href="/z/d/graphic/67711.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef115617" href="/z/d/graphic/115617.html" rel="external">algorithm 1</a>). A significant proportion of children with KD have a concurrent infection; therefore, ascribing the fever to such an infection or to KD requires clinical judgment. Additional clinical and laboratory features are often used to guide diagnosis in children who have fewer than five criteria for KD (incomplete KD). (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/15689.html" rel="external">"Incomplete (atypical) Kawasaki disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incomplete KD and delayed diagnosis in infants and adults</strong> –<strong> </strong>Infants and possibly adults are more likely to present with incomplete KD. Infants are at greater risk for cardiovascular sequelae, possibly due in part to a delay in diagnosis and intervention. Thus, infants six months of age or younger with unexplained fever for at least seven days should be evaluated for KD, even if they have no clinical findings of KD. Adults with delayed diagnosis also have a higher rate of morbidity. (See <a class="local">'Infants'</a> above and <a class="local">'Adults'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – KD is most commonly confused with infectious exanthems of childhood. The presence of clinical features not commonly found in KD, including exudative conjunctivitis, exudative pharyngitis, discrete intraoral lesions, bullous or vesicular rash, splenomegaly, and/or generalized lymphadenopathy, suggest another diagnosis  (<a class="graphic graphic_table graphicRef53802" href="/z/d/graphic/53802.html" rel="external">table 3</a>). Nonetheless, KD is sufficiently pleomorphic that none of these findings can definitively exclude the diagnosis. Children with KD can have concurrent infections, particularly with viruses circulating in the community at the time of their diagnosis. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Burns JC, Glodé MP. Kawasaki syndrome. Lancet 2004; 364:533.</a></li><li><a class="nounderline abstract_t">McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017; 135:e927.</a></li><li><a class="nounderline abstract_t">Morens DM, Anderson LJ, Hurwitz ES. National surveillance of Kawasaki disease. Pediatrics 1980; 65:21.</a></li><li><a class="nounderline abstract_t">Huang GY, Ma XJ, Huang M, et al. Epidemiologic pictures of Kawasaki disease in Shanghai from 1998 through 2002. J Epidemiol 2006; 16:9.</a></li><li><a class="nounderline abstract_t">Baker AL, Lu M, Minich LL, et al. Associated symptoms in the ten days before diagnosis of Kawasaki disease. J Pediatr 2009; 154:592.</a></li><li><a class="nounderline abstract_t">Burns JC, Mason WH, Glode MP, et al. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. J Pediatr 1991; 118:680.</a></li><li><a class="nounderline abstract_t">Ozdemir H, Ciftçi E, Tapisiz A, et al. Clinical and epidemiological characteristics of children with Kawasaki disease in Turkey. J Trop Pediatr 2010; 56:260.</a></li><li><a class="nounderline abstract_t">Cai Z, Zuo R, Liu Y. Characteristics of Kawasaki disease in older children. Clin Pediatr (Phila) 2011; 50:952.</a></li><li><a class="nounderline abstract_t">Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 2005; 47:232.</a></li><li><a class="nounderline abstract_t">Fukushige J, Takahashi N, Ueda Y, Ueda K. Incidence and clinical features of incomplete Kawasaki disease. Acta Paediatr 1994; 83:1057.</a></li><li><a class="nounderline abstract_t">Sung RY, Ng YM, Choi KC, et al. Lack of association of cervical lymphadenopathy and coronary artery complications in Kawasaki disease. Pediatr Infect Dis J 2006; 25:521.</a></li><li><a class="nounderline abstract_t">Germain BF, Moroney JD, Guggino GS, et al. Anterior uveitis in Kawasaki disease. J Pediatr 1980; 97:780.</a></li><li><a class="nounderline abstract_t">Nomura Y, Arata M, Koriyama C, et al. A severe form of Kawasaki disease presenting with only fever and cervical lymphadenopathy at admission. J Pediatr 2010; 156:786.</a></li><li><a class="nounderline abstract_t">Smith LB, Newburger JW, Burns JC. Kawasaki syndrome and the eye. Pediatr Infect Dis J 1989; 8:116.</a></li><li><a class="nounderline abstract_t">Eberhard BA, Sundel RP, Newburger JW, et al. Psoriatic eruption in Kawasaki disease. J Pediatr 2000; 137:578.</a></li><li><a class="nounderline abstract_t">Kishimoto S, Muneuchi J, Takahashi Y, et al. Psoriasiform skin lesion and supprative acrodermatitis associated with Kawasaki disease followed by the treatment with infliximab: a case report. Acta Paediatr 2010; 99:1102.</a></li><li><a class="nounderline abstract_t">Ergin S, Karaduman A, Demirkaya E, et al. Plaque psoriasis induced after Kawasaki disease. Turk J Pediatr 2009; 51:375.</a></li><li><a class="nounderline abstract_t">Liao YC, Lee JY. Psoriasis in a 3-month-old infant with Kawasaki disease. Dermatol Online J 2009; 15:10.</a></li><li><a class="nounderline abstract_t">Uehara R, Igarashi H, Yashiro M, et al. Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Guérin inoculation site. Pediatr Infect Dis J 2010; 29:430.</a></li><li><a class="nounderline abstract_t">Wang S, Best BM, Burns JC. Periungual desquamation in patients with Kawasaki disease. Pediatr Infect Dis J 2009; 28:538.</a></li><li><a class="nounderline abstract_t">April MM, Burns JC, Newburger JW, Healy GB. Kawasaki disease and cervical adenopathy. Arch Otolaryngol Head Neck Surg 1989; 115:512.</a></li><li><a class="nounderline abstract_t">Kanegaye JT, Van Cott E, Tremoulet AH, et al. Lymph-node-first presentation of Kawasaki disease compared with bacterial cervical adenitis and typical Kawasaki disease. J Pediatr 2013; 162:1259.</a></li><li><a class="nounderline abstract_t">Dominguez SR, Anderson MS, El-Adawy M, Glodé MP. Preventing coronary artery abnormalities: a need for earlier diagnosis and treatment of Kawasaki disease. Pediatr Infect Dis J 2012; 31:1217.</a></li><li><a class="nounderline abstract_t">Printz BF, Sleeper LA, Newburger JW, et al. Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. J Am Coll Cardiol 2011; 57:86.</a></li><li><a class="nounderline abstract_t">Gong GW, McCrindle BW, Ching JC, Yeung RS. Arthritis presenting during the acute phase of Kawasaki disease. J Pediatr 2006; 148:800.</a></li><li><a class="nounderline abstract_t">Melish ME. Kawasaki syndrome: a 1986 perspective. Rheum Dis Clin North Am 1987; 13:7.</a></li><li><a class="nounderline abstract_t">Colomba C, La Placa S, Saporito L, et al. Intestinal Involvement in Kawasaki Disease. J Pediatr 2018; 202:186.</a></li><li><a class="nounderline abstract_t">Yanagawa H, Tuohong Z, Oki I, et al. Effects of gamma-globulin on the cardiac sequelae of Kawasaki disease. Pediatr Cardiol 1999; 20:248.</a></li><li><a class="nounderline abstract_t">Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998; 17:1144.</a></li><li><a class="nounderline abstract_t">Chang FY, Hwang B, Chen SJ, et al. Characteristics of Kawasaki disease in infants younger than six months of age. Pediatr Infect Dis J 2006; 25:241.</a></li><li><a class="nounderline abstract_t">Yeom JS, Woo HO, Park JS, et al. Kawasaki disease in infants. Korean J Pediatr 2013; 56:377.</a></li><li><a class="nounderline abstract_t">Salgado AP, Ashouri N, Berry EK, et al. High Risk of Coronary Artery Aneurysms in Infants Younger than 6 Months of Age with Kawasaki Disease. J Pediatr 2017; 185:112.</a></li><li><a class="nounderline abstract_t">Sève P, Lega JC. [Kawasaki disease in adult patients]. Rev Med Interne 2011; 32:17.</a></li><li><a class="nounderline abstract_t">Wolff AE, Hansen KE, Zakowski L. Acute Kawasaki disease: not just for kids. J Gen Intern Med 2007; 22:681.</a></li><li><a class="nounderline abstract_t">Fraison JB, Sève P, Dauphin C, et al. Kawasaki disease in adults: Observations in France and literature review. Autoimmun Rev 2016; 15:242.</a></li><li><a class="nounderline abstract_t">Cunha BA, Pherez FM, Alexiadis V, et al. Adult Kawasaki's disease with myocarditis, splenomegaly, and highly elevated serum ferritin levels. Heart Lung 2010; 39:164.</a></li><li><a class="nounderline abstract_t">Nofech-Mozes Y, Garty BZ. Thrombocytopenia in Kawasaki disease: a risk factor for the development of coronary artery aneurysms. Pediatr Hematol Oncol 2003; 20:597.</a></li><li><a class="nounderline abstract_t">Shike H, Kanegaye JT, Best BM, et al. Pyuria associated with acute Kawasaki disease and fever from other causes. Pediatr Infect Dis J 2009; 28:440.</a></li><li><a class="nounderline abstract_t">Watanabe T, Abe Y, Sato S, et al. Sterile pyuria in patients with Kawasaki disease originates from both the urethra and the kidney. Pediatr Nephrol 2007; 22:987.</a></li><li><a class="nounderline abstract_t">Eladawy M, Dominguez SR, Anderson MS, Glodé MP. Abnormal liver panel in acute kawasaki disease. Pediatr Infect Dis J 2011; 30:141.</a></li><li><a class="nounderline abstract_t">Dengler LD, Capparelli EV, Bastian JF, et al. Cerebrospinal fluid profile in patients with acute Kawasaki disease. Pediatr Infect Dis J 1998; 17:478.</a></li><li><a class="nounderline abstract_t">Hicks RV, Melish ME. Kawasaki syndrome. Pediatr Clin North Am 1986; 33:1151.</a></li><li><a class="nounderline abstract_t">Salo E, Pesonen E, Viikari J. Serum cholesterol levels during and after Kawasaki disease. J Pediatr 1991; 119:557.</a></li><li><a class="nounderline abstract_t">Newburger JW, Burns JC, Beiser AS, Loscalzo J. Altered lipid profile after Kawasaki syndrome. Circulation 1991; 84:625.</a></li><li><a class="nounderline abstract_t">Cabana VG, Gidding SS, Getz GS, et al. Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease. Pediatr Res 1997; 42:651.</a></li><li><a class="nounderline abstract_t">Nakamura Y, Yashiro M, Uehara R, et al. Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 2004; 46:33.</a></li><li><a class="nounderline abstract_t">Kawasaki T. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi 1967; 16:178.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control. Kawasaki disease — New York. MMWR Morb Mortal Wkly Rep 1980; 29:61.</a></li><li><a class="nounderline abstract_t">Sundel RP. Update on the treatment of Kawasaki disease in childhood. Curr Rheumatol Rep 2002; 4:474.</a></li><li class="breakAll">Royal College of Paediatrics and Child Health (RCPCH). Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-%20inflammatory%20syndrome-20200501.pdf (Accessed on May 14, 2020).</li><li><a class="nounderline abstract_t">Yanagihara R, Todd JK. Acute febrile mucocutaneous lymph node syndrome. Am J Dis Child 1980; 134:603.</a></li><li><a class="nounderline abstract_t">Barron KS. Kawasaki disease in children. Curr Opin Rheumatol 1998; 10:29.</a></li><li><a class="nounderline abstract_t">Turnier JL, Anderson MS, Heizer HR, et al. Concurrent Respiratory Viruses and Kawasaki Disease. Pediatrics 2015; 136:e609.</a></li><li><a class="nounderline abstract_t">Benseler SM, McCrindle BW, Silverman ED, et al. Infections and Kawasaki disease: implications for coronary artery outcome. Pediatrics 2005; 116:e760.</a></li><li><a class="nounderline abstract_t">Jaggi P, Kajon AE, Mejias A, et al. Human adenovirus infection in Kawasaki disease: a confounding bystander? Clin Infect Dis 2013; 56:58.</a></li><li><a class="nounderline abstract_t">Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324:1633.</a></li><li><a class="nounderline abstract_t">Binstadt BA, Levine JC, Nigrovic PA, et al. Coronary artery dilation among patients presenting with systemic-onset juvenile idiopathic arthritis. Pediatrics 2005; 116:e89.</a></li><li><a class="nounderline abstract_t">Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; 2:1055.</a></li><li><a class="nounderline abstract_t">Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315:341.</a></li><li><a class="nounderline abstract_t">Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004; 114:1708.</a></li><li><a class="nounderline abstract_t">Minich LL, Sleeper LA, Atz AM, et al. Delayed diagnosis of Kawasaki disease: what are the risk factors? Pediatrics 2007; 120:e1434.</a></li></ol></div><div id="topicVersionRevision">Topic 6417 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302199" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Kawasaki syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28356445" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7355030" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : National surveillance of Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16369103" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiologic pictures of Kawasaki disease in Shanghai from 1998 through 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19038400" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Associated symptoms in the ten days before diagnosis of Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2019921" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20007257" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical and epidemiological characteristics of children with Kawasaki disease in Turkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21628347" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Characteristics of Kawasaki disease in older children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15771703" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7841704" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Incidence and clinical features of incomplete Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16732150" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lack of association of cervical lymphadenopathy and coronary artery complications in Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7431172" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Anterior uveitis in Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20097355" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A severe form of Kawasaki disease presenting with only fever and cervical lymphadenopathy at admission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2468129" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Kawasaki syndrome and the eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11035843" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Psoriatic eruption in Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20219036" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Psoriasiform skin lesion and supprative acrodermatitis associated with Kawasaki disease followed by the treatment with infliximab: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19950847" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Plaque psoriasis induced after Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19951646" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Psoriasis in a 3-month-old infant with Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20032807" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Guérin inoculation site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19483521" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Periungual desquamation in patients with Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2923695" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Kawasaki disease and cervical adenopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23305955" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Lymph-node-first presentation of Kawasaki disease compared with bacterial cervical adenitis and typical Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22760536" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Preventing coronary artery abnormalities: a need for earlier diagnosis and treatment of Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21185506" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16769390" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Arthritis presenting during the acute phase of Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2888164" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Kawasaki syndrome: a 1986 perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30029859" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intestinal Involvement in Kawasaki Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10368448" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effects of gamma-globulin on the cardiac sequelae of Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9877364" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16511387" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Characteristics of Kawasaki disease in infants younger than six months of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24223598" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Kawasaki disease in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28408126" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : High Risk of Coronary Artery Aneurysms in Infants Younger than 6 Months of Age with Kawasaki Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20537446" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : [Kawasaki disease in adult patients].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17443379" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Acute Kawasaki disease: not just for kids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26631821" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Kawasaki disease in adults: Observations in France and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20207278" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Adult Kawasaki's disease with myocarditis, splenomegaly, and highly elevated serum ferritin levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14578029" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Thrombocytopenia in Kawasaki disease: a risk factor for the development of coronary artery aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19319019" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pyuria associated with acute Kawasaki disease and fever from other causes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17323086" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sterile pyuria in patients with Kawasaki disease originates from both the urethra and the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20861758" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Abnormal liver panel in acute kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9655538" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cerebrospinal fluid profile in patients with acute Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3532006" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Kawasaki syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1919886" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Serum cholesterol levels during and after Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1860206" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Altered lipid profile after Kawasaki syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9357939" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15043662" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6062087" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Kawasaki disease—New York</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12427361" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Update on the treatment of Kawasaki disease in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12427361" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Update on the treatment of Kawasaki disease in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6104439" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Acute febrile mucocutaneous lymph node syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9448987" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Kawasaki disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26304824" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Concurrent Respiratory Viruses and Kawasaki Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16322132" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Infections and Kawasaki disease: implications for coronary artery outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23011145" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Human adenovirus infection in Kawasaki disease: a confounding bystander?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1709446" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930186" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Coronary artery dilation among patients presenting with systemic-onset juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6209513" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : High-dose intravenous gammaglobulin for Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2426590" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The treatment of Kawasaki syndrome with intravenous gamma globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15574639" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18025079" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Delayed diagnosis of Kawasaki disease: what are the risk factors?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
